A fully human BCMA-directed CAR-T product showed clinical activity in patients with relapsed/refractory multiple myeloma.
All articles by Christina Bennett, MS
A CAR-T therapy for myeloma that is manufactured using a unique process showed clinical activity and appeared safe, even in the outpatient setting.
Hypogammaglobulinemia often occurs in patients with chronic lymphocytic leukemia who receive CAR-T, but there is no standard way to manage it.
A novel assay was shown to precisely quantify CAR T cells in circulation and distinguish responders from nonresponders.
Responses lasted for a median of 21.8 months, and patients had a median PFS of 18.8 months.
Idecabtagene vicleucel showed clinical benefit and no toxicity concerns in patients with relapsed and/or refractory multiple myeloma.
A CAR-T therapy that targets B-cell maturation antigen showed clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma.
Allogeneic T cells with off-the-shelf potential showed preclinical activity against SARS-CoV-2 and are now being evaluated in a clinical trial.
Latest News Your top articles for ThursdayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses